<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116155">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02118168</url>
  </required_header>
  <id_info>
    <org_study_id>ISS T-002 EF-UP</org_study_id>
    <nct_id>NCT02118168</nct_id>
  </id_info>
  <brief_title>Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002</brief_title>
  <acronym>ISST-002 EF-UP</acronym>
  <official_title>OBSERVATIONAL STUDY FOR THE EXTENDED FOLLOW-UP OF THE PATIENTS ENROLLED IN THE PHASE II THERAPEUTIC CLINICAL TRIAL ISS T-002</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ensoli, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Superiore di Sanità</source>
  <oversight_info>
    <authority>Italy: AIFA</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational study to prospectively follow-up the patients enrolled in the ISS T-002
      clinical trial up to 132 weeks. The primary endpoint of this study is to evaluate the
      persistence, in term of frequency, magnitude and quality, of the anti-Tat humoral and
      cellular immune response in the HIV-1 infected individuals who participated to the ISS T-002
      and who have received at least 3 immunizations. The secondary endpoint is to define and
      validate novel laboratory tests for future efficacy clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>anti-Tat humoral immune response</measure>
    <time_frame>Every 3 months, up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint of the study is to evaluate the persistence, in term of frequency, magnitude, and quality of the anti-Tat humoral immune response in HAART-treated patients previously immunize with Tat in the ISS T-002 phase II clinical trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testing of the additional Immunological parameters detailed below as a second line testing</measure>
    <time_frame>Every 3 months, up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary endpoint of the study is to identify and validate immunological  testing for future efficacy vaccine clinical trials, as follows: Lymphoproliferative response to Tat/in vitro anti-Tat γIFN, IL4 and IL2 production; In vitro neutralization of Tat activity (Tat/Env uptake); Lymphocyte subsets; Anti-Tat IgG subclasses; Epitope mapping of anti-Tat IgM and IgG; Anti-HIV regulatory and structural proteins antibodies; ADCC; Neutralization of Tat activity by rescue assay; Neutralization of primary HIV isolates; Anti-CCR5 and Anti-CD4  antibodies; Lymphoproliferative response to Env, mitogens and recall antigens In vitro γIFN, IL4 and IL2 production in response to Tat (ICS) and to Env (ICS/Elispot); B cells phenotype; Characterization of Treg cells; PBMC ICS for granzyme, perforin, cytokines and chemokines; Th1 and Th2 cytokines and chemokines; Lymphocytes spontaneous cell death; Bcell cloning; Characterization of clono-specific antibodies; Serum/plasma determination of sCD4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testing of virological parameters detalied below, as a second line testing</measure>
    <time_frame>Every 3 months, up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary endpoint of the study is to identify and validate virological testing for future efficacy vaccine clinical trials, as follows: HIV-1 plasma viremia (viral RNA copies) HIV-1 sequencing and virus phylogenetic analysis Genotypic resistance Viral tropism Anti-HBV antibodies HBV antigens (HbsAg, HbeAg) Anti-HCV antibodies and plasma viremia HHV-8 antibodies and plasma viremia HIV-1 Proviral DNA copies</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">168</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <description>All patients that participated to the therapeutic phase II trial of the Tat vaccine &quot;ISS T-002&quot; and that received at least 3 immunizations and reached 48-weeks of follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention is forseen in this Observational Study</description>
    <arm_group_label>No treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HAART-treated patients who participated to the therapeutic phase II trial of the Tat
        vaccine &quot;ISS T-002&quot; and received at least 3 immunizations and reached 48-weeks of
        follow-up.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous participation in the ISS T-002 trial, having received at least 3
             immunizations;

          -  A follow-up of at least 48 weeks during the ISS T-002 study;

          -  Availability to participate in the extended follow-up study;

          -  Signed informed consent.

        Exclusion Criteria:

          -  The absence of any of the above criteria will exclude the subjects from the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Ensoli, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Istituto Superiore di Sanità</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Ensoli, MD, PHD</last_name>
    <phone>+39 06 4990</phone>
    <phone_ext>3209</phone_ext>
    <email>barbara.ensoli@iss.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Divisione di Malattie Infettive Azienda Ospedaliera S. Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Divisione Malattie Infettive - AO Ospedale Policlinico Consorziale</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gioacchino Angarano, MD</last_name>
      <phone>+ 39 080 5593</phone>
      <phone_ext>120</phone_ext>
      <email>gioacchino.angarano@uniba.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ambulatorio Malattie Infettive - AO Universitaria</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Malattie Infettive - Ospedale S.M. Annunziata</name>
      <address>
        <city>Firenze</city>
        <zip>50012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Mazzotta, MD</last_name>
      <phone>+ 39 055 2496</phone>
      <phone_ext>233</phone_ext>
      <email>francesco.mazzotta@asf.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U. O. di Malattie Infettive Centro di Ricerca e Cura Patologie HIV correlate - Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriano Lazzarin, MD</last_name>
      <phone>+39 02-26437</phone>
      <phone_ext>939</phone_ext>
      <email>lazzarin.adriano@hsr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto di Malattie Infettive e Tropicali - AO Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Galli, MD</last_name>
      <phone>+39 02 39042</phone>
      <phone_ext>451</phone_ext>
      <email>massimo.galli@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Divisione di Malattie Infettive - AO Universitaria Policlinico</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Mussini, MD</last_name>
      <phone>+39 059 4222</phone>
      <phone_ext>827</phone_ext>
      <email>crimus@unimore.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O.C. Dermatologia Infettiva ed Allergologica - IFO San Gallicano</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Latini, MD</last_name>
      <phone>+39 06-5266</phone>
      <phone_ext>2804</phone_ext>
      <email>a.latini@ifo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.iss.it/aids/</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Superiore di Sanità</investigator_affiliation>
    <investigator_full_name>Barbara Ensoli, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HAART</keyword>
  <keyword>Tat Protein</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
